U.S. Food and Drug Administration regulatory update

FDA will hold a public workshop on April 25-26 to discuss therapies to treat myalgic encephalomyelitis and chronic fatigue syndrome (CFS). The workshop will gather patient perspectives and identify quantitative outcome measures to determine if disease symptoms improve with specific drug treatments. The workshop is part of a series of activities planned by the agency to discuss bringing safe and effective drugs for myalgic encephalomyelitis and CFS to market. ...